Autres langues Soligenix, Inc.

Actions

SNGX

US8342236044

Recherche biotechnologique et médicale

Temps Différé Nasdaq 20:45:18 07/10/2026			Varia. 5j.	Varia. 1 janv.
0,3579 ^USD	-0,03%		-1,38%	-73,36%

21/09	Soligenix approuve l'amendement aux statuts de la société	CI
07/08	Soligenix, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

21/09	Soligenix Approves Amendment to the Company?S Second Amended and Restated Certificate of Incorporation
07/08	Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
08/06	Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine
28/05	Soligenix - increases maximum offering under sales agreement by $2.96 million
27/05	Top Premarket Gainers
26/05	Soligenix Announces Suitability of Vaccine Platform for Bundibugyo Virus
08/05	Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
08/05	Soligenix announces recent updates and first quarter 2026 financial results
08/05	Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
28/04	Soligenix Inc Announces Interim Results from Phase 3 Flash2 Trial Evaluating Hybryte in Treatment of Cutaneous T-Cell Lymphoma
10/04	BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
02/04	Soligenix Inc. Announces Positive Clinical Results For HyBryte In Comparative Study Against Valchlor In Treatment Of Cutaneous T-Cell Lymphoma
31/03	Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Soligenix announces recent accomplishments and year end 2025 financial results
31/03	Soligenix, Inc. Auditor Raises 'Going Concern' Doubt
23/03	Soligenix, Inc. Presents Hybryte? Treatment Results At Us Cutaneous Lymphoma Consortium Annual Workshop
23/03	Soligenix : HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
19/03	IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
10/03	Soligenix, Inc. Receives Promising Innovative Medicine Designation for SGX945 in the United Kingdom
26/02	Soligenix, Inc. Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for Sgx945 for the Treatment of Behcet's Disease
23/01	Soligenix enters sales agreement with Rodman
19/12	Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)
18/12	Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology
18/12	Positive clinical results from phase 2 trial of SGX945
17/12	Soligenix, Inc. Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis